{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:46:18Z","timestamp":1793893578730,"version":"4.8.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jpet.2025.103525","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T19:05:54Z","timestamp":1740769554000},"page":"103525","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Small molecule interleukin (IL) 17A\/A antagonists and antibodies blocking both IL17A\/A and IL17A\/F demonstrate equivalent degrees of efficacy in preclinical models of skin and joint inflammation"],"prefix":"10.1016","volume":"392","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9876-6770","authenticated-orcid":false,"given":"Eric R.","family":"Goedken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Lipovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Kannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine L.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Ciura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sage E.","family":"Foley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7915-8334","authenticated-orcid":false,"given":"Kristine E.","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian A.","family":"Goess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujatha","family":"Gopalakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen N.","family":"Greszler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan A.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"Leys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob J.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne L.","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay C.","family":"Panchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Paulsboe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Perham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley L.","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter F.","family":"Slivka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron","family":"Srikumaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Webster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma L.","family":"Wambeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haizhong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria E.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"McGaraughty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prisca","family":"Honore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpet.2025.103525_bib1","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.it.2017.01.006","article-title":"IL-17 signaling: the Yin and the Yang","volume":"38","author":"Amatya","year":"2017","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jpet.2025.103525_bib2","doi-asserted-by":"crossref","first-page":"8828","DOI":"10.1021\/acs.jmedchem.2c00422","article-title":"Discovery of an oral, rule of 5 compliant, interleukin 17A protein-protein interaction modulator for the potential treatment of psoriasis and other inflammatory diseases","volume":"65","author":"Andrews","year":"2022","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.jpet.2025.103525_bib3","doi-asserted-by":"crossref","DOI":"10.1186\/ar3370","article-title":"Analysis of IL-17+cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response","volume":"13","author":"Appel","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jpet.2025.103525_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001005","article-title":"Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study","volume":"5","author":"Baraliakos","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.jpet.2025.103525_bib5","unstructured":"Brace GN, Chappell RE, Deboves HJC, Foley AM, Foulkes G, Jones EP, Lecomte FC, Quincey JR, Schulze MSED, Selby MD, et\u00a0al (2018) Spirocyclic indolines as IL-17 modulators. WO2018229079A1."},{"key":"10.1016\/j.jpet.2025.103525_bib6","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.3389\/fimmu.2018.01682","article-title":"The IL-17 family of cytokines in psoriasis: IL-17A and beyond","volume":"9","author":"Brembilla","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jpet.2025.103525_bib7","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/1529-0131(199905)42:5<963::AID-ANR15>3.0.CO;2-E","article-title":"Human interleukin-17: a T cell\u2013derived proinflammatory cytokine produced by the rheumatoid synovium","volume":"42","author":"Chabaud","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpet.2025.103525_bib8","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/cr.2007.35","article-title":"A\u00a0novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses","volume":"17","author":"Chang","year":"2007","journal-title":"Cell Res"},{"key":"10.1016\/j.jpet.2025.103525_bib9","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/cpt.3185","article-title":"Safety, tolerability, and pharmacokinetics of an oral small molecule inhibitor of IL-17A (LY3509754): a phase I randomized placebo-controlled study","volume":"115","author":"Datta-Mannan","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jpet.2025.103525_bib10","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.3899\/jrheum.221022","article-title":"Long-term safety and efficacy of ixekizumab in patients with axial spondyloarthritis: 3-year data from the COAST program","volume":"50","author":"Deodhar","year":"2023","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.jpet.2025.103525_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7573\/dic.212570","article-title":"Brodalumab in psoriasis: evidence to date and clinical potential","volume":"8","author":"Foulkes","year":"2019","journal-title":"Drugs Context"},{"key":"10.1016\/j.jpet.2025.103525_bib12","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.3390\/ijms21041275","article-title":"Interleukin-17A and keratinocytes in psoriasis","volume":"21","author":"Furue","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jpet.2025.103525_bib13","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nri3707","article-title":"The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing","volume":"14","author":"Gaffen","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jpet.2025.103525_bib14","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jdermsci.2018.08.001","article-title":"Mechanistic and pharmacological assessment of murine IL-23 mediated psoriasiform dermatitis; implications for drug discovery","volume":"92","author":"Gauld","year":"2018","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.jpet.2025.103525_bib15","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1124\/jpet.119.258046","article-title":"Inhibition of interleukin-23\u2013mediated inflammation with a novel small molecule inverse agonist of ROR\u03b3t","volume":"371","author":"Gauld","year":"2019","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.jpet.2025.103525_bib16","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","article-title":"Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation","volume":"77","author":"Glatt","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jpet.2025.103525_bib17","article-title":"Identification and structure-based drug design of cell-active inhibitors of interleukin 17A at a novel C-terminal site","volume":"12","author":"Goedken","year":"2022","journal-title":"Sci Rep-uk"},{"key":"10.1016\/j.jpet.2025.103525_bib18","doi-asserted-by":"crossref","first-page":"8906","DOI":"10.1038\/s41598-017-08360-9","article-title":"The human IL-17A\/F heterodimer: a two-faced cytokine with unique receptor recognition properties","volume":"7","author":"Goepfert","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jpet.2025.103525_bib19","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrd.2016.213","article-title":"DNA-encoded chemistry: enabling the deeper sampling of chemical space","volume":"16","author":"Goodnow","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jpet.2025.103525_bib20","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jpet.2025.103525_bib21","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.cyto.2013.07.022","article-title":"IL-17 family: cytokines, receptors and signaling","volume":"64","author":"Gu","year":"2013","journal-title":"Cytokine"},{"key":"10.1016\/j.jpet.2025.103525_bib22","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S1016-8478(23)13153-0","article-title":"Expression of IL-17 homologs and their receptors in the synovial cells of rheumatoid arthritis patients","volume":"19","author":"Hwang","year":"2005","journal-title":"Mol Cells"},{"key":"10.1016\/j.jpet.2025.103525_bib23","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1021\/acsmedchemlett.6b00464","article-title":"Structure based design of non-natural peptidic macrocyclic Mcl-1 inhibitors","volume":"8","author":"Johannes","year":"2017","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.jpet.2025.103525_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/5fedb3bf-c9c2-4862-9ad5-23c8ae484ad5","article-title":"Neutrophils are essential as a source of IL-17 in the effector phase of arthritis","volume":"8","author":"Katayama","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jpet.2025.103525_bib25","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","article-title":"Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials","volume":"403","author":"Kimball","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jpet.2025.103525_bib26","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jaci.2016.06.038","article-title":"\u03b2-Defensin 2 is a responsive biomarker of IL-17A\u2013driven skin pathology in patients with psoriasis","volume":"139","author":"Kolbinger","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jpet.2025.103525_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107925","article-title":"Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: physical and pharmacological properties underlie the observed clinical efficacy and safety","volume":"229","author":"Kolbinger","year":"2022","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jpet.2025.103525_bib28","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/1346-8138.14899","article-title":"Characterization of psoriasiform dermatitis induced by systemic injection of interleukin-23 minicircles in mice","volume":"46","author":"Leys","year":"2019","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jpet.2025.103525_bib29","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1172\/JCI38702","article-title":"IL-17 produced by neutrophils regulates IFN-\u03b3\u2013mediated neutrophil migration in mouse kidney ischemia-reperfusion injury","volume":"120","author":"Li","year":"2010","journal-title":"J\u00a0Clin Investig"},{"key":"10.1016\/j.jpet.2025.103525_bib30","doi-asserted-by":"crossref","first-page":"7791","DOI":"10.4049\/jimmunol.179.11.7791","article-title":"An IL-17F\/A heterodimer protein is produced by mouse Th17 cells and induces airway neutrophil recruitment","volume":"179","author":"Liang","year":"2007","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jpet.2025.103525_bib31","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/JIR.S100940","article-title":"Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A","volume":"9","author":"Liu","year":"2016","journal-title":"J\u00a0Inflamm Res"},{"key":"10.1016\/j.jpet.2025.103525_bib32","article-title":"Binding site elucidation and structure guided design of macrocyclic IL-17A antagonists","volume":"6","author":"Liu","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jpet.2025.103525_bib33","article-title":"Inhibiting complex IL-17A and IL-17RA interactions with a linear peptide","volume":"6","author":"Liu","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jpet.2025.103525_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.594735","article-title":"The IL-23\/IL-17 pathway in inflammatory skin diseases: from bench to bedside","volume":"11","author":"Liu","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jpet.2025.103525_bib35","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1038\/ncomms2880","article-title":"Crystal structures of interleukin 17A and its complex with IL-17 receptor A","volume":"4","author":"Liu","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.jpet.2025.103525_bib36","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41590-019-0367-4","article-title":"IL-17 metabolically reprograms activated fibroblastic reticular cells for proliferation and survival","volume":"20","author":"Majumder","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jpet.2025.103525_bib37","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s40744-024-00684-z","article-title":"Matching-adjusted indirect comparison of the 52-week efficacy of bimekizumab versus secukinumab and ixekizumab for the treatment of radiographic axial spondyloarthritis","volume":"11","author":"Maksymowych","year":"2024","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.jpet.2025.103525_bib38","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/cpt.3135","article-title":"Comparative effectiveness of bimekizumab in psoriatic arthritis: a model-based meta-analysis of American College of Rheumatology response criteria","volume":"115","author":"Maloney","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jpet.2025.103525_bib39","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Mark","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jpet.2025.103525_bib40","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1189\/jlb.0313113","article-title":"Th17 memory cells: live long and proliferate","volume":"94","author":"McGeachy","year":"2013","journal-title":"J\u00a0Leukoc Biol"},{"key":"10.1016\/j.jpet.2025.103525_bib41","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.immuni.2019.03.021","article-title":"The IL-17 family of cytokines in health and disease","volume":"50","author":"McGeachy","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.jpet.2025.103525_bib42","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","article-title":"Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)","volume":"401","author":"McInnes","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jpet.2025.103525_bib43","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/jan.13818","article-title":"The fear of needles: a systematic review and meta-analysis","volume":"75","author":"McLenon","year":"2019","journal-title":"J\u00a0Adv Nurs"},{"key":"10.1016\/j.jpet.2025.103525_bib44","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41577-022-00746-9","article-title":"IL-17 and IL-17-producing cells in protection versus pathology","volume":"23","author":"Mills","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jpet.2025.103525_bib45","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/eji.200839120","article-title":"IL-17-producing \u03b3\u03b4 T cells","volume":"39","author":"O\u2019Brien","year":"2009","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jpet.2025.103525_bib46","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","article-title":"Brodalumab, an anti\u2013interleukin-17\u2013receptor antibody for psoriasis","volume":"366","author":"Papp","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jpet.2025.103525_bib47","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/ni.3726","article-title":"IL-17+ \u03b3\u03b4 T cells as kick-starters of inflammation","volume":"18","author":"Papotto","year":"2017","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jpet.2025.103525_bib48","doi-asserted-by":"crossref","first-page":"6456","DOI":"10.1021\/acs.jmedchem.3c02397","article-title":"Discovery of small molecule interleukin 17A inhibitors with novel binding mode and stoichiometry: optimization of DNA-encoded chemical library hits to in\u00a0vivo active compounds","volume":"67","author":"Ramos","year":"2024","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.jpet.2025.103525_bib49","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jpet.2025.103525_bib50","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.4049\/jimmunol.1001001","article-title":"IL-23\u2013mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A","volume":"186","author":"Rizzo","year":"2011","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jpet.2025.103525_bib51","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1021\/acsmedchemlett.1c00470","article-title":"Imidazo[1,2-b]pyridazines as IL-17A inhibitors for treating psoriasis, rheumatoid arthritis, and multiple sclerosis","volume":"12","author":"Sabnis","year":"2021","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.jpet.2025.103525_bib52","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/cei.12376","article-title":"IL-17 subtypes in inflammatory arthritis","volume":"177","author":"Sarkar","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jpet.2025.103525_bib53","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1111\/1346-8138.16899","article-title":"Importance of PLD2 in an IL-23 driven psoriasiform dermatitis model and potential link to human psoriasis","volume":"50","author":"Su","year":"2023","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jpet.2025.103525_bib54","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s40744-017-0086-y","article-title":"Secukinumab in active rheumatoid arthritis after anti-TNF\u03b1 therapy: a randomized, double-blind placebo-controlled phase 3 study","volume":"4","author":"Tahir","year":"2017","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.jpet.2025.103525_bib55","unstructured":"Taylor M, Terrett NK, Connors WH, Seigal BA, Snedeker C, Hale SP, Briggs TF, Favaloro FG, Cipriani TJ, Yan D, et\u00a0al (2013) Macrocyclic compounds for modulating IL-17. WO2013116682A1."},{"key":"10.1016\/j.jpet.2025.103525_bib56","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1016\/S2665-9913(23)00101-7","article-title":"Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"5","author":"Venhoff","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jpet.2025.103525_bib57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004456","article-title":"Brothers in arms: Th17 and Treg responses in Candida albicans immunity","volume":"10","author":"Whibley","year":"2014","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jpet.2025.103525_bib58","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1080\/13543776.2022.2143264","article-title":"Small molecule modulators of IL-17A\/IL-17RA: a patent review (2013\u20132021)","volume":"32","author":"Zhang","year":"2022","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.jpet.2025.103525_bib59","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1964420","article-title":"A\u00a0non-clinical comparative study of IL-23 antibodies in psoriasis","volume":"13","author":"Zhou","year":"2021","journal-title":"mAbs"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525397387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525397387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T22:31:27Z","timestamp":1762209087000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356525397387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0022356525397387"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103525","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Small molecule interleukin (IL) 17A\/A antagonists and antibodies blocking both IL17A\/A and IL17A\/F demonstrate equivalent degrees of efficacy in preclinical models of skin and joint inflammation","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103525","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103525"}}